Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period: A placebo-controlled, randomized trial

Thorsten M. Leucker, Michael J. Blaha, Steven R. Jones, Michael A. Vavuranakis, Marlene S. Williams, Hong Lai, Thomas H. Schindler, Jacqueline Latina, Steven P. Schulman, Gary Gerstenblith

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)419-421
Number of pages3
Issue number4
StatePublished - Jul 28 2020


  • acute coronary syndrome
  • cholesterol, LDL
  • evolocumab
  • secondary prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this